X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs LUPIN LTD - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES LUPIN LTD DIVIS LABORATORIES/
LUPIN LTD
 
P/E (TTM) x 30.0 19.9 150.8% View Chart
P/BV x 5.2 2.7 192.8% View Chart
Dividend Yield % 1.0 0.9 102.5%  

Financials

 DIVIS LABORATORIES   LUPIN LTD
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
LUPIN LTD
Mar-17
DIVIS LABORATORIES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,2221,750 69.8%   
Low Rs7841,384 56.7%   
Sales per share (Unadj.) Rs153.1387.4 39.5%  
Earnings per share (Unadj.) Rs39.956.6 70.5%  
Cash flow per share (Unadj.) Rs44.676.8 58.0%  
Dividends per share (Unadj.) Rs10.007.50 133.3%  
Dividend yield (eoy) %1.00.5 208.3%  
Book value per share (Unadj.) Rs201.8298.9 67.5%  
Shares outstanding (eoy) m265.47451.58 58.8%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x6.64.0 162.0%   
Avg P/E ratio x25.127.7 90.8%  
P/CF ratio (eoy) x22.520.4 110.3%  
Price / Book Value ratio x5.05.2 94.8%  
Dividend payout %25.013.2 189.0%   
Avg Mkt Cap Rs m266,266707,513 37.6%   
No. of employees `0009.716.8 58.0%   
Total wages/salary Rs m4,68728,495 16.4%   
Avg. sales/employee Rs Th4,175.010,418.3 40.1%   
Avg. wages/employee Rs Th481.51,697.0 28.4%   
Avg. net profit/employee Rs Th1,089.31,523.0 71.5%   
INCOME DATA
Net Sales Rs m40,643174,943 23.2%  
Other income Rs m7491,065 70.3%   
Total revenues Rs m41,392176,008 23.5%   
Gross profit Rs m14,46044,931 32.2%  
Depreciation Rs m1,2339,122 13.5%   
Interest Rs m231,525 1.5%   
Profit before tax Rs m13,95335,349 39.5%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3499,785 34.2%   
Profit after tax Rs m10,60425,575 41.5%  
Gross profit margin %35.625.7 138.5%  
Effective tax rate %24.027.7 86.7%   
Net profit margin %26.114.6 178.5%  
BALANCE SHEET DATA
Current assets Rs m40,105119,542 33.5%   
Current liabilities Rs m6,59561,206 10.8%   
Net working cap to sales %82.533.3 247.3%  
Current ratio x6.12.0 311.4%  
Inventory Days Days11976 156.0%  
Debtors Days Days8190 89.8%  
Net fixed assets Rs m19,995131,660 15.2%   
Share capital Rs m531903 58.8%   
"Free" reserves Rs m53,043134,073 39.6%   
Net worth Rs m53,574134,976 39.7%   
Long term debt Rs m056,478 0.0%   
Total assets Rs m61,585266,073 23.1%  
Interest coverage x618.424.2 2,558.0%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.70.7 100.4%   
Return on assets %17.310.2 169.4%  
Return on equity %19.818.9 104.5%  
Return on capital %26.119.3 135.4%  
Exports to sales %00-   
Imports to sales %25.20-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259NA-   
Fx inflow Rs m35,38481,885 43.2%   
Fx outflow Rs m10,39921,506 48.4%   
Net fx Rs m24,98560,378 41.4%   
CASH FLOW
From Operations Rs m11,49341,148 27.9%  
From Investments Rs m-11,372-25,287 45.0%  
From Financial Activity Rs m-934,332 -2.1%  
Net Cashflow Rs m2820,193 0.1%  

Share Holding

Indian Promoters % 52.0 46.6 111.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.8 11.3 104.4%  
FIIs % 19.0 31.9 59.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.1 170.3%  
Shareholders   31,796 98,259 32.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  SANOFI INDIA  DR. DATSONS LABS  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS